Comparative Pharmacology
Head-to-head clinical analysis: ETRAFON 2 10 versus QUIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ETRAFON 2 10 versus QUIDE.
ETRAFON 2-10 vs QUIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
ETRAFON 2-10 is a combination of the phenothiazine antipsychotic perphenazine and the tricyclic antidepressant amitriptyline. Perphenazine blocks dopamine D2 receptors, reducing dopaminergic neurotransmission in the mesolimbic pathway, while amitriptyline inhibits serotonin and norepinephrine reuptake, enhancing monoaminergic signaling.
Quetiapine acts as an antagonist at multiple neurotransmitter receptors in the brain, including serotonin 5-HT2A, dopamine D2, histamine H1, and adrenergic α1 receptors. It also has partial agonist activity at serotonin 5-HT1A receptors. This atypical antipsychotic action is mediated primarily through 5-HT2A and D2 antagonism.
1-2 tablets (perphenazine 2 mg / amitriptyline 10 mg) orally 3-4 times daily; max 8 tablets/day.
5 mg orally once daily, with or without food.
None Documented
None Documented
The terminal elimination half-life is approximately 9-10 hours for perphenazine and 18-24 hours for amitriptyline; amitriptyline's active metabolite nortriptyline has a half-life of 18-44 hours, necessitating once-daily dosing for maintenance.
2-4 hours (prolonged in renal impairment, requiring dose adjustment)
Elimination is primarily renal (50-70% as metabolites, <5% unchanged) and biliary/fecal (30-50% as metabolites).
Primarily renal (80% as unchanged drug); minor fecal (20%)
Category C
Category C
Antipsychotic/Antidepressant Combination
Antipsychotic